Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137031 | 0.80 | PDGFRB (0.33) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL5369688 | 0.79 | KDR (0.51) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL7135648 | 0.78 | IGF1R (0.45) | RETPDGFRBKMT2A | |
| SCHEMBL5368595 | 0.76 | RET (0.65) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL5365604 | 0.76 | KDR (0.47) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL14519118 | 0.73 | KDR (0.62) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL5365192 | 0.71 | RET (0.40) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL5988083 | 0.71 | KDR (0.36) | RETPDPK1KDRPDGFRBFGFR1 | |
| SCHEMBL5364515 | 0.71 | PDGFRB (0.62) | RETKDRPDGFRBFGFR1MAPT | |
| SCHEMBL6298676 | 0.71 | RET (0.61) | RETPDPK1KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | RET 283/4885PDPK1 31/4885KDR 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.